BIOMAT Database Logo BIOMAT Database Logo

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. 1996

R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA.

OBJECTIVE This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy. METHODS Patients with stage IIIB or IV NSCLC with measurable disease in nonradiated fields were eligible. Other eligibility criteria were Zubrod performance status (PS) < or = 2 and adequate renal and liver function. TPT was administered at a dose of 1.5 mg/m2/d for 5 days over 30 minutes every 21 days. Of 48 registered patients, 40 were fully assessable. Nineteen patients had adenocarcinoma (AD), 14 squamous carcinoma (SCC), and seven poorly differentiated carcinoma. RESULTS Six patients (15%) achieved a partial remission (PR) (durations: 8, 14, 18, 28, 56, and 61 weeks) and four patients a minor response; 10 patients had stable disease and 20 patients progressive disease. The PR rate was 36% (five of 14 patients) in patients with SCC versus 4% (one of 26 patients) in those with other histologies (P = .014). The overall median survival time was 38 weeks and 30% of patients were alive at 1 year. Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 76% and 10% of courses administered, respectively. No grade 3 to 4 nonhematologic toxicities were observed. Grade 1 or 2 nonhematologic toxicities consisted of nausea (46% and 5%), vomiting (31% and 7%), and fatigue (53% and 16%). CONCLUSIONS TPT at the dose and schedule used has moderate antitumor activity in NSCLC; its activity is mostly limited to patients with SCC. TPT is well tolerated, with myelosuppression of short duration being the most common and limiting toxicity.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.
February 2004, Annals of oncology : official journal of the European Society for Medical Oncology,
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer.
January 2009, Lung cancer (Amsterdam, Netherlands),
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
January 2008, Respirology (Carlton, Vic.),
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
May 2010, Clinical lung cancer,
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
June 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
January 2016, Chemotherapy,
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II study of oral topotecan in advanced non-small cell lung cancer.
March 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.
March 1993, Journal of the National Cancer Institute,
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
January 2003, Oncology,
R Perez-Soler, and F V Fossella, and B S Glisson, and J S Lee, and W K Murphy, and D M Shin, and B L Kemp, and J J Lee, and J Kane, and R A Robinson, and S M Lippman, and J M Kurie, and M H Huber, and M N Raber, and W K Hong
A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer.
January 2005, Medical oncology (Northwood, London, England),
Copied contents to your clipboard!